Chairman_NN
&_CC
Chief_NN
Executive_NN
Officers_NN
statement_NOMZ
GSK_NN
demonstrates_VPRT [PRIV]
continued_JJ
strength_NN
Building_GER
a_DT
strong_JJ
and_PHC
diverse_JJ
R&D_NN
pipeline_NN
people_NN
._.
The_DT
World_NN
Health_NN
Organization_NOMZ
target_NN
Acknowledgements_NOMZ
licences_NN
,_,
but_CC
gives_VPRT
assurances_NN
that_DEMP
this_DEMP
will_PRMD
not_XX0
of_PIN
generic_JJ
competition_NOMZ
,_,
have_VPRT [PEAS]
seen_VBN [PRIV]
their_TPP3
earnings_GER
Key_NN
features_NN
of_PIN
2003_CD
2003_CD
provided_VBD
the_DT
clearest_JJ
evidence_NN
yet_RB
of_PIN
our_FPP1
is_VPRT
to_TO
eliminate_VB
LF_NN
by_PIN
2020_CD
,_,
by_PIN
which_WDT [PIRE]
time_NN
we_FPP1
During_PIN
the_DT
year_NN
there_EX
were_VBD
a_DT
number_NN
of_PIN
changes_NN
be_VB [PASS]
abused_VBN
._.
Nevertheless_CONJ
,_,
the_DT
external_JJ
pressure_NN
fall_NN
significantly_RB
._.
success_NN
in_PIN
creating_VBG
the_DT
most_EMPH
productive_JJ
R&D_NN
expect_VPRT [PRIV]
to_TO
have_VB [PEAS]
donated_VBN
six_CD
billion_CD
treatments_NOMZ
of_PIN
to_PIN
the_DT
Board_NN
._.
The_DT
Board_NN
now_TIME
benefits_VPRT
from_PIN
the_DT
to_TO
amend_VB
the_DT
TRIPS_NN
agreement_NOMZ
,_,
which_WDT [SERE]
protects_VPRT
organization_NOMZ
in_PIN
the_DT
industry_NN
._.
At_PIN
our_FPP1
R&D_NN
our_FPP1
medicine_NN
albendazole_NN
,_,
worth_JJ
around_PLACE
direct_JJ
presence_NN
of_PIN
Dr_NN
Tachi_NN
Yamada_NN
,_,
who_WP
has_VPRT
intellectual_JJ
property_NN
,_,
remains_VPRT
strong_JJ
._.
2004_CD
will_PRMD
be_VB [BEMA]
a_DT
year_NN
of_PIN
transition_NOMZ
for_PIN
GSK_NN
._.
By_PIN
Day_NN
in_PIN
December_NN
we_FPP1
demonstrated_VBD [PRIV]
how_RB [WHCL]
our_FPP1
$_$
1_CD
billion_CD
._.
This_DEMP
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
pharmaceutical_JJ
great_JJ
knowledge_NN
and_PHC
experience_NN
in_PIN
medical_JJ
the_DT
end_NN
of_PIN
2004_CD
the_DT
companys_NN
profile_VPRT
will_PRMD
be_VB [BEMA]
1_CD
New_JJ
products_NN
accounted_VBD
for_PIN
25_CD
%_NN
re-designed_JJ
R&D_NN
operation_NOMZ
is_VPRT
delivering_VBG
a_DT
industrys_RB
largest_JJ
ever_RB
donation_NOMZ
programs_NN
._.
practice_NN
as_RB
well_RB
as_IN
the_DT
pharmaceutical_JJ
industry_NN
._.
This_DEMP
is_VPRT [BEMA]
not_XX0
the_DT
place_NN
to_TO
debate_VB
the_DT
rights_NN
transformed_VBN
._.
As_RB
well_RB
as_IN
having_VBG
one_CD
of_PIN
the_DT
most_EMPH
of_PIN
total_JJ
pharmaceutical_JJ
turnover_NN
._.
product_NN
pipeline_NN
of_PIN
exceptional_JJ
diversity_NOMZ
,_,
quality_NOMZ
We_FPP1
reduced_VBD
the_DT
not-for-profit_JJ
prices_NN
of_PIN
our_FPP1
HIV_NN
Three_CD
new_JJ
Non-Executive_JJ
Directors_NN
joined_VBD
the_DT
and_CC
wrongs_NN
of_PIN
these_DEMO
challenges_NN
to_PIN
the_DT
broadly-based_JJ
product_NN
portfolios_NN
in_PIN
the_DT
industry_NN
,_,
and_ANDC
quantity_NOMZ
that_TSUB
will_PRMD
drive_VB
the_DT
future_JJ
growth_NN
treatments_NOMZ
twice_RB
in_PIN
2003_CD
,_,
taking_VBG [PRESP]
the_DT
price_NN
of_PIN
Board_NN
during_PIN
the_DT
year_NN
:_:
Larry_NN
Culp_NN
,_,
President_NN
pharmaceutical_JJ
industrys_NN
traditional_JJ
business_NOMZ
from_PIN
2005_CD
onwards_NN
we_FPP1
will_PRMD [SPAU]
also_RB
have_VB
one_CD
of_PIN
the_DT
2_CD
Trading_GER
profit_NN
of_PIN
6.9_CD
billion_CD
on_PIN
of_PIN
the_DT
company_NN
._.
Combivir_NN
down_RB
from_PIN
$_$
1.70_CD
to_TO
just_EMPH
65_CD
cents_NN
a_DT
of_PIN
Danaher_NN
Corporation_NOMZ
:_:
Crispin_NN
Davis_NN
,_,
Chief_NN
model_NN
._.
It_PIT
is_VPRT [BEMA]
the_DT
place_NN
for_PIN
us_FPP1
to_TO
reassure_VB
lowest_JJ
exposures_NN
to_PIN
patent_NN
expiries_NN
measured_VBN
as_IN
turnover_NN
of_PIN
21.4_CD
billion_CD
._.
However_CONJ
,_,
much_QUAN
more_EMPH
needs_VPRT
to_TO
be_VB [PASS]
done_VBN [PROD]
Executive_NN
of_PIN
Reed_NN
Elsevier_NN
PLC_NN
:_:
and_ANDC
Sir_NN
Robert_NN
shareholders_NN
that_TOBJ
we_FPP1
have_VPRT
every_QUAN
aspect_NN
of_PIN
a_DT
percentage_NN
of_PIN
turnover_NN
._.
At_PIN
the_DT
same_JJ
time_NN
,_,
we_FPP1
We_FPP1
now_TIME
have_VPRT
148_CD
projects_NN
in_PIN
clinical_JJ
to_TO
tackle_VB
the_DT
enormous_JJ
HIV_NN
AIDS_NN
crisis_NN
._.
Real_JJ
Wilson_NN
,_,
Chairman_NN
of_PIN
BG_NN
Group_NN
plc._NN
._.
They_TPP3
each_QUAN
that_DEMO
model_NN
under_IN
review_NN
in_PIN
order_NN
to_TO
continue_VB
expect_VB [PRIV]
to_TO
see_VB [PRIV]
a_DT
big_JJ
increase_NN
in_PIN
the_DT
number_NN
of_PIN
3_CD
Ten_CD
major_JJ
products_NN
recorded_VBN
development_NOMZ
._.
These_DEMP
span_VPRT
a_DT
variety_NN
of_PIN
therapeutic_JJ
progress_NN
will_PRMD [SPAU]
only_DWNT
be_VB [PASS]
made_VBN
if_COND
responsibility_NOMZ
is_VPRT
bring_VB
many_QUAN
years_NN
of_PIN
experience_NN
and_CC
successful_JJ
the_DT
development_NOMZ
of_PIN
medicines_NN
on_PIN
a_DT
basis_NN
which_WDT [WHOBJ]
major_JJ
new_JJ
compounds_NN
entering_VBG [WZPRES]
Phase_NN
III_NN
trials_NN
double-digit_JJ
growth_NN
._.
areas_NN
and_CC
encompass_VB
a_DT
number_NN
of_PIN
pioneering_JJ
shared_VBN
by_PIN
all_QUAN
sectors_NN
of_PIN
global_JJ
society_NN
track_NN
records_NN
in_PIN
different_JJ
industries_NN
._.
Their_TPP3
reconciles_NN
our_FPP1
responsibility_NOMZ
to_PIN
society_NN
with_PIN
a_DT
fair_JJ
from_PIN
our_FPP1
promising_JJ
pipeline_NN
._.
approaches_NN
to_TO
treating_VBG
patients_NN
,_,
including_VBG
governments_NOMZ
,_,
international_JJ
agencies_NN
and_CC
undoubted_JJ
skills_NN
further_RB
strengthen_VB
the_DT
Board_NN
._.
We_FPP1
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
to_PIN
4_CD
Regulatory_NN
approval_NN
for_PIN
ten_NN
exciting_JJ
new_JJ
compounds_NN
in_PIN
the_DT
areas_NN
of_PIN
companies_NN
such_JJ
as_IN
GSK_NN
._.
change_NN
with_PIN
the_DT
times_NN
imaginatively_RB
,_,
flexibly_RB
and_CC
Broad_NN
product_NN
portfolio_NN
drives_VPRT
growth_NN
important_JJ
new_JJ
products_NN
and_CC
new_JJ
indications_NOMZ
._.
The_DT
Sir_NN
Roger_NN
Hurn_NN
and_PHC
Paul_NN
Allaire_NN
left_VBD
the_DT
Board_NN
effectively_RB
,_,
and_ANDC
to_TO
fight_VB
for_PIN
what_WP
we_FPP1
believe_VPRT [PRIV]
will_PRMD
GSKs_NN
ability_NOMZ
to_TO
continue_VB
delivering_VBG
robust_JJ
148_CD
projects_NN
include_VPRT
83_CD
new_JJ
chemical_NN
entities_NOMZ
We_FPP1
are_VPRT [BEMA]
very_AMP
proud_PRED
of_PIN
our_FPP1
global_JJ
community_NOMZ
in_PIN
June_NN
._.
Dr_NN
Michle_NN
Barzach_NN
,_,
John_NN
McArthur_NN
best_JJ
serve_VPRT
the_DT
long_JJ
term_NN
interests_NN
of_PIN
GSK_NN
as_IN
one_CD
pharmaceuticals_NN
sales_NN
growth_NN
,_,
despite_PIN
these_DEMO
NCEs_NN
,_,
45_CD
product_NN
line_NN
extensions_NN
PLEs_NN
and_CC
20_CD
investment_NOMZ
of_PIN
338_CD
million_CD
,_,
5.3_CD
per_PIN
cent_NN
of_PIN
the_DT
and_CC
Donald_NN
McHenry_NN
will_PRMD
step_VB
down_RB
from_PIN
the_DT
of_PIN
the_DT
worlds_NN
leading_VBG [WZPRES]
producers_NN
of_PIN
medicines_NN
._.
generic_JJ
challenges_NN
,_,
is_VPRT [BEMA]
primarily_RB
due_PRED
to_PIN
its_PIT
vaccines_NN
._.
Forty_CD
six_CD
of_PIN
the_DT
NCEs_NN
are_VPRT [BEMA]
now_TIME
in_PIN
clinical_JJ
Groups_NN
pre-tax_JJ
profit_NN
._.
This_DEMP
included_VBD
125_CD
million_CD
Board_NN
after_IN
the_DT
AGM_NN
in_PIN
May_POMD
._.
We_FPP1
express_VPRT
our_FPP1
exceptionally_RB
broad_JJ
product_NN
portfolio_NN
of_PIN
fastphases_NN
II_NN
and_PHC
III_NN
registration_NOMZ
and_CC
we_FPP1
expect_VPRT [PRIV]
to_PIN
for_PIN
the_DT
Group_NN
's_POS
Patient_NN
Assistance_NN
Programs_NN
and_PHC
appreciation_NOMZ
to_PIN
each_QUAN
of_PIN
them_TPP3
for_PIN
their_TPP3
Robust_JJ
financial_JJ
performance_NN
in_PIN
2003_CD
growing_VBG
,_,
high-value_JJ
products_NN
._.
GSK_NN
is_VPRT [BEMA]
a_DT
global_JJ
make_VPRT
a_DT
record_NN
number_NN
of_PIN
filings_GER
over_IN
the_DT
next_JJ
other_JJ
initiatives_NN
for_PIN
low-income_JJ
groups_NN
in_PIN
the_DT
contribution_NOMZ
to_PIN
the_DT
company_NN
and_CC
for_PIN
their_TPP3
During_PIN
2003_CD
,_,
our_FPP1
business_NOMZ
performance_NN
earnings_GER
leader_NN
in_PIN
several_QUAN
therapeutic_JJ
areas_NN
including_VBG [WZPRES]
five_CD
years_NN
._.
As_IN
many_QUAN
as_IN
20_CD
of_PIN
these_DEMO
compounds_NN
USA_NN
and_CC
105_CD
million_CD
of_PIN
humanitarian_JJ
product_NN
dedicated_VBN
and_CC
effective_JJ
service_NN
to_PIN
the_DT
Board_NN
._.
per_PIN
share_NN
grew_VBD
ten_CD
per_PIN
cent_NN
,_,
which_WDT [SERE]
was_VBD [BEMA]
in_PIN
line_NN
respiratory_JJ
,_,
anti-viral_JJ
,_,
central_JJ
nervous_JJ
system_NN
,_,
have_VPRT
the_DT
potential_NN
to_TO
reach_VB
blockbuster_NN
status_NN
._.
with_PIN
the_DT
guidance_NN
we_FPP1
had_VBD [PEAS]
issued_VBN
._.
Trading_GER
profit_NN
diabetes_NN
and_PHC
vaccines_NN
._.
In_CONJ
conclusion_NULL
,_,
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
and_CC
the_DT
rose_VBD
nine_CD
per_PIN
cent_NN
to_PIN
6.9_CD
billion_CD
and_CC
we_FPP1
had_VBD
an_DT
Included_VBN
in_PIN
the_DT
many_QUAN
promising_JJ
compounds_NN
Governance_NN
Corporate_NN
Executive_NN
Team_NN
,_,
we_FPP1
thank_VPRT
you_SPP2
,_,
our_FPP1
operating_GER
cash_NN
flow_NN
of_PIN
7.0_CD
billion_CD
._.
We_FPP1
also_RB
The_DT
company_NN
now_TIME
has_VPRT [PEAS]
ten_VBN
major_JJ
products_NN
highlighted_VBN [WZPAST]
in_PIN
December_NN
were_VBD
:_:
016_CD
,_,
a_DT
first_JJ
of_PIN
its_PIT
The_DT
Financial_NN
Reporting_GER
Council_NN
's_POS
new_JJ
Combined_VBN
shareholders_NN
,_,
for_PIN
your_SPP2
continued_JJ
support_NN
raised_VBD
the_DT
dividend_NN
to_PIN
41_CD
pence_NN
._.
accounting_GER
for_PIN
7.6_CD
billion_CD
of_PIN
sales_NN
growing_VBG [WZPRES]
kind_NN
dual_JJ
kinase_NN
inhibitor_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
Code_NN
on_PIN
Corporate_NN
Governance_NN
was_VBD [PASS]
published_VBN
through_PIN
this_DEMO
challenging_JJ
time_NN
._.
These_DEMP
include_VPRT
breast_NN
and_PHC
lung_NN
cancer_NN
:_:
Cervarix_NN
,_,
a_DT
vaccine_NN
with_PIN
in_PIN
2003_CD
._.
The_DT
Board_NN
supports_VPRT
the_DT
New_NN
Code_NN
and_PHC
Total_NN
pharmaceutical_JJ
turnover_NN
grew_VBD
five_CD
per_PIN
cent_NN
Seretide_NN
Advair_NN
for_PIN
asthma_NN
and_CC
chronic_JJ
Trading_GER
Profit_NN
growth_NN
the_DT
potential_NN
to_TO
prevent_VB
more_EMPH
than_PIN
70_CD
per_PIN
cent_NN
has_VPRT [PEAS]
moved_VBN [SUAV]
quickly_RB
to_TO
bring_VB
GSK_NN
's_POS
governance_NN
to_TO
just_EMPH
over_IN
18_CD
billion_CD
,_,
with_PIN
US_FPP1
sales_NN
also_RB
up_IN
obstructive_JJ
pulmonary_JJ
disease_NN
COPD_NN
which_WDT [WHOBJ]
of_PIN
cervical_JJ
cancers_NN
:_:
162_CD
,_,
a_DT
next-generation_JJ
procedures_NN
substantially_RB
in_PIN
line_NN
with_PIN
the_DT
best_JJ
five_CD
per_PIN
cent_NN
to_PIN
9.4_CD
billion_CD
._.
This_DEMO
achievement_NOMZ
grew_VBD
39_CD
per_PIN
cent_NN
during_PIN
the_DT
year_NN
to_PIN
2.2_CD
billion_CD
,_,
anti-depressant_JJ
:_:
Lp-PLA2_NN
inhibitors_NN
which_WDT [WHSUB]
target_VPRT
practices_NN
that_TSUB
flow_VPRT
from_PIN
the_DT
Code_NN
._.
confirms_VPRT [PUBV]
the_DT
underlying_JJ
strength_NN
and_PHC
resilience_NN
of_PIN
and_CC
is_VPRT [BEMA]
now_TIME
one_CD
of_PIN
the_DT
top_JJ
ten_NN
pharmaceutical_JJ
Trading_GER
Profit_NN
a_DT
newly_RB
identified_VBN
risk_NN
factor_NN
for_PIN
heart_NN
disease_NN
:_:
our_FPP1
business_NOMZ
,_,
particularly_RB
given_VBN
continued_VBN
generic_JJ
brands_NN
in_PIN
the_DT
world_NN
._.
Our_FPP1
diabetes_NN
treatments_NOMZ
odiparcil_NN
,_,
a_DT
novel_NN
anti-blood_JJ
clotting_GER
treatment_NOMZ
,_,
up_IN
9_CD
%_NN
to_PIN
erosion_NN
during_PIN
the_DT
year_NN
to_PIN
sales_NN
of_PIN
Augmentin_NN
Avandia_NN
Avandamet_NN
also_RB
continue_VPRT
to_TO
perform_VB
Sir_NN
Christopher_NN
Hogg_NN
JP_NN
Garnier_NN
and_CC
381_CD
,_,
the_DT
first_JJ
dual_JJ
action_NOMZ
COX-2_NN
inhibitor_NN
and_CC
the_DT
introduction_NOMZ
of_PIN
generic_JJ
competition_NOMZ
to_TO
well_RB
,_,
with_PIN
sales_NN
of_PIN
0.9_CD
billion_CD
,_,
up_RB
24_CD
per_PIN
cent_NN
._.
Chairman_NN
Chief_NN
Executive_NN
Officer_NN
6.9_CD
billion_CD
targeting_VBG
both_DT
inflammatory_JJ
and_PHC
neuropathic_JJ
Paxil_NN
in_PIN
September_NN
._.
Products_NN
such_JJ
as_IN
Valtrex_NN
for_PIN
herpes_NN
and_CC
Lamictal_JJ
pain_NN
._.
Building_GER
on_PIN
our_FPP1
strong_JJ
heritage_NN
in_PIN
for_PIN
epilepsy_NN
are_VPRT
growing_VBG
very_AMP
strongly_AMP
and_CC
are_VPRT [BEMA]
respiratory_JJ
medicine_NN
,_,
we_FPP1
are_VPRT [SPAU]
also_RB
developing_VBG
a_DT
The_DT
Consumer_NN
Healthcare_NN
business_NOMZ
also_RB
did_VBD
well_RB
,_,
now_DPAR
approaching_VBG
blockbuster_NN
status_NN
._.
Also_RB
,_,
both_DT
next-generation_JJ
Seretide_NN
Advair_NN
a_DT
once-daily_JJ
making_VBG
a_DT
trading_GER
profit_NN
of_PIN
603_CD
million_CD
for_PIN
the_DT
year_NN
,_,
our_FPP1
vaccines_NN
and_PHC
HIV_NN
AIDS_NN
businesses_NOMZ
have_VPRT
sales_NN
combination_NOMZ
of_PIN
a_DT
new_JJ
long-acting_JJ
corticosteroid_NN
,_,
up_RB
16_CD
per_PIN
cent_NN
._.
698_CD
,_,
and_ANDC
a_DT
long-acting_JJ
selective_JJ
beta2_JJ
agonist_NN
,_,
797_CD
,_,
developed_VBN [PASTP]
with_PIN
Theravance_NN
Inc._NN
2004_CD
a_DT
year_NN
of_PIN
transition_NOMZ
before_IN
returning_VBG
New_NN
product_NN
launches_NN
in_PIN
2003_CD
and_CC
2004_CD
to_PIN
growth_NN
in_PIN
2005_CD
Several_QUAN
new_JJ
and_PHC
important_JJ
products_NN
were_VBD [BEMA]
Corporate_JJ
responsibility_NOMZ
2004_CD
will_PRMD
be_VB [BEMA]
a_DT
particularly_RB
challenging_JJ
year_NN
as_IN
introduced_VBN
in_PIN
2003_CD
._.
Highlights_NN
included_VBD
US_FPP1
Corporate_NN
responsibility_NOMZ
has_VPRT
particular_JJ
resonance_NN
we_FPP1
see_VPRT [PRIV]
the_DT
full_JJ
impact_NN
of_PIN
generic_JJ
competition_NOMZ
launches_NN
of_PIN
Wellbutrin_NN
XL_NN
,_,
a_DT
new_JJ
and_CC
improved_VBN
for_PIN
the_DT
pharmaceutical_JJ
sector_NN
._.
Our_FPP1
business_NOMZ
is_VPRT [BEMA]
to_PIN
Paxil_NN
and_CC
the_DT
introduction_NOMZ
of_PIN
generic_JJ
version_NN
of_PIN
the_DT
anti-depressant_JJ
,_,
and_ANDC
Levitra_NN
for_PIN
01_CD
02_CD
03_CD
creating_VBG
medicines_NN
to_TO
treat_VB
and_PHC
prevent_VB
disease_NN
Wellbutrin_NN
._.
Together_RB
,_,
these_DEMO
products_NN
had_VBD
erectile_JJ
dysfunction_NOMZ
._.
Approval_NN
was_VBD [PASS]
received_VBN
These_DEMP
are_VPRT [PASS]
based_VBN
on_PIN
business_NOMZ
performance_NN
results_NN
._.
something_QUPR
that_DEMO
society_NN
needs_NN
and_PHC
values_NN
._.
At_PIN
the_DT
US_FPP1
sales_NN
of_PIN
2.1_CD
billion_CD
last_JJ
year_NN
._.
For_PIN
most_EMPH
for_PIN
Lexiva_NN
for_PIN
HIV_NN
AIDS_NN
,_,
Advair_NN
for_PIN
COPD_NN
and_CC
All_QUAN
percentage_NN
growth_NN
rates_NN
are_VPRT [BEMA]
at_PIN
constant_JJ
same_JJ
time_NN
,_,
healthcare_NN
and_CC
the_DT
way_NN
it_PIT
is_VPRT [PASS]
delivered_VBN
companies_NN
,_,
a_DT
threat_NN
to_PIN
sales_NN
on_PIN
this_DEMO
scale_NN
would_PRMD
Lamictal_VB
for_PIN
bi-polar_JJ
disorder_NN
in_PIN
the_DT
USA_NN
,_,
and_ANDC
exchange_NN
rates_NN
,_,
unless_COND
otherwise_CONJ
stated_VBN [PUBV]
._.
and_ANDC
funded_JJ
provoke_VPRT
much_QUAN
debate_NN
._.
But_CC
we_FPP1
expect_VPRT [PRIV]
to_TO
be_VB [BEMA]
able_PRED
to_PIN
Avandamet_NN
for_PIN
diabetes_NN
in_PIN
Europe_NN
._.
See_NN
Business_NOMZ
Operating_GER
Review_NN
page_NN
22_CD
._.
Corporate_JJ
Responsibility_NOMZ
Report_NN
sets_VPRT
out_PIN
the_DT
weather_NN
the_DT
impact_NN
well_RB
partly_DWNT
because_CAUS
of_PIN
our_FPP1
issues_NN
that_TOBJ
we_FPP1
face_VPRT
in_PIN
this_DEMO
area_NN
and_CC
explains_VPRT [PUBV]
size_NN
,_,
partly_DWNT
through_PIN
the_DT
introduction_NOMZ
of_PIN
improved_VBN
We_FPP1
plan_VPRT
to_TO
make_VB
several_QUAN
significant_JJ
product_NN
how_RB
we_FPP1
are_VPRT
addressing_VBG
them_TPP3
._.
Where_RB
possible_JJ
,_,
versions_NN
of_PIN
these_DEMO
medicines_NN
and_CC
partly_DWNT
by_PIN
driving_VBG
launches_NN
and_PHC
filings_GER
during_PIN
2004_CD
._.
These_DEMP
include_VPRT
:_:
performance_NN
measures_NN
are_VPRT [PASS]
included_VBN
to_TO
show_VB [PRIV]
growth_NN
of_PIN
the_DT
other_JJ
key_JJ
products_NN
in_PIN
our_FPP1
broad_JJ
solifenacin_NN
for_PIN
over-active_JJ
bladder_NN
developed_VBD
our_FPP1
progress_NN
._.
In_PIN
fact_NN
,_,
we_FPP1
expect_VPRT [PRIV]
to_TO
be_VB [BEMA]
able_PRED
to_TO
deliver_VB
with_PIN
our_FPP1
partner_NN
Yamanouchi_NN
Pharmaceuticals_NN
2004_CD
earnings_GER
per_PIN
share_NN
EPS_NN
at_PIN
least_JJ
in_PIN
line_NN
with_PIN
Ltd_NN
of_PIN
Japan_NN
:_:
Avandaryl_NN
,_,
a_DT
fixed-dose_JJ
Significant_JJ
achievements_NOMZ
this_DEMO
year_NN
include_VPRT
the_DT
business_NOMZ
performance_NN
EPS_NN
in_PIN
2003_CD
at_PIN
constant_JJ
combination_NOMZ
treatment_NOMZ
which_WDT [WHSUB]
will_PRMD [SPAU]
further_RB
extend_VB
progress_NN
we_FPP1
are_VPRT
making_VBG
in_PIN
our_FPP1
programs_NN
for_PIN
exchange_NN
rates_NN
,_,
before_IN
returning_VBG
to_PIN
growth_NN
in_PIN
the_DT
Avandia_NN
family_NN
of_PIN
treatments_NOMZ
for_PIN
type_NN
2_CD
the_DT
developing_VBG
world_NN
,_,
such_JJ
as_IN
our_FPP1
efforts_NN
to_PIN
2005_CD
._.
This_DEMP
will_PRMD
represent_VB
a_DT
solid_JJ
achievement_NOMZ
for_PIN
diabetes_NN
:_:
and_ANDC
Epivir_NN
plus_PIN
Ziagen_NN
,_,
the_DT
first_JJ
onceeliminate_JJ
lymphatic_JJ
filariasis_NN
LF_NN
or_CC
elephantiasis_NN
,_,
GSK_NN
._.
Many_QUAN
other_JJ
pharmaceutical_JJ
companies_NN
,_,
daily_JJ
combination_NOMZ
HIV_NN
AIDS_NN
treatment_NOMZ
to_TO
be_VB [BEMA]
a_DT
debilitating_VBG
disease_NN
affecting_VBG [WZPRES]
120_CD
million_CD
which_WDT
have_VPRT [PEAS]
faced_VBN
a_DT
similar_JJ
loss_NN
of_PIN
sales_NN
as_CONJ
a_NULL
result_NULL
available_JJ
in_PIN
a_DT
single_JJ
tablet_NN
._.
02_CD
Annual_JJ
Review_NN
2003_CD
million_CD
6,053_CD
6,694_CD
6,920_CD
A_DT
day_NN
to_TO
deliver_VB
Our_FPP1
unique_JJ
R&D_NN
structure_NN
starts_VPRT
to_TO
deliver_VB
._.
GSKs_NN
radical_JJ
redesign_NN
of_PIN
its_PIT
R&D_NN
organization_NOMZ
is_VPRT [BEMA]
a_DT
bold_JJ
move_NN
to_TO
tackle_VB
the_DT
problem_NN
of_PIN
R&D_NN
productivity_NOMZ
,_,
a_DT
real_JJ
challenge_NN
to_PIN
the_DT
global_JJ
pharmaceutical_JJ
industry_NN
._.
The_DT
impact_NN
of_PIN
the_DT
reorganisation_NOMZ
can_POMD [SPAU]
now_TIME
be_VB [PASS]
seen_VBN [PRIV]
in_PIN
GSKs_NN
broad_JJ
and_PHC
deep_JJ
pipeline_NN
of_PIN
medicines_NN
across_PLACE
a_DT
spectrum_NN
of_PIN
key_JJ
therapeutic_JJ
areas_NN
._.
The_DT
projects_NN
that_TOBJ
GSK_NN
now_TIME
has_VPRT
in_PIN
clinical_JJ
development_NOMZ
comprise_VPRT
a_DT
number_NN
of_PIN
pioneering_JJ
approaches_NN
Asthma_NN
affects_VPRT
100-150_CD
million_CD
people_NN
worldwide_JJ
,_,
killing_VBG [PRESP]
180,000_CD
each_QUAN
We_FPP1
have_VPRT
vaccines_NN
in_PIN
clinical_JJ
development_NOMZ
against_PIN
numerous_JJ
to_TO
treating_VBG
patients_NN
in_PIN
need_NN
._.
Our_FPP1
new_JJ
structure_NN
is_VPRT
working_VBG
well_RB
,_,
said_VBD [PUBV]
Tachi_NN
Yamada_NN
,_,
Chairman_NN
of_PIN
R&D_NN
._.
Seretide_NN
Advair_NN
has_VPRT [PEAS]
revolutionised_VBN
the_DT
treatment_NOMZ
of_PIN
asthma_NN
and_CC
chronic_JJ
diseases_NN
affecting_VBG [WZPRES]
all_QUAN
age_NN
brackets_NN
,_,
from_PIN
children_NN
to_PIN
the_DT
developing_VBG
more_EMPH
quality_NOMZ
compounds_NN
than_PIN
ever_RB
before_RB
._.
This_DEMP
is_VPRT
enabling_VBG
us_FPP1
to_TO
renew_VB
our_FPP1
pipeline_NN
in_PIN
disease_NN
areas_NN
obstructive_JJ
pulmonary_JJ
disease_NN
COPD_NN
._.
One_CD
of_PIN
our_FPP1
development_NOMZ
compounds_NN
,_,
elderly_JJ
,_,
and_ANDC
in_PIN
all_QUAN
regions_NN
,_,
from_PIN
the_DT
developed_VBN
to_PIN
the_DT
685698_CD
,_,
is_VPRT [BEMA]
a_DT
third_JJ
generation_NOMZ
inhaled_VBD
corticosteroid_JJ
._.
It_PIT
promises_VPRT [PUBV]
to_TO
be_VB [BEMA]
a_DT
oncedeveloping_JJ
world_NN
._.
In_PIN
2004_CD
,_,
we_FPP1
plan_VPRT
to_TO
file_VB
our_FPP1
Rotarix_NN
vaccine_NN
where_RB
we_FPP1
are_VPRT
leaders_NN
such_JJ
as_IN
respiratory_JJ
and_PHC
psychiatry_JJ
and_CC
to_TO
build_VB
strong_JJ
portfolios_NN
in_PIN
areas_NN
such_JJ
as_IN
oncology_JJ
a-day_JJ
treatment_NOMZ
and_CC
to_TO
offer_VB
greater_JJ
potency_NN
._.
to_TO
help_VB
stem_VB
rotavirus_NN
gastroenteritis_NN
,_,
a_DT
disease_NN
that_DEMP
is_VPRT
and_CC
cardiovascular_JJ
disease_NN
._.
estimated_VBN [PRIV]
to_TO
lead_VB
to_PIN
the_DT
death_NN
of_PIN
one_CD
child_NN
every_QUAN
minute_NN
._.
Two_CD
thirds_NN
of_PIN
Americans_NN
are_VPRT [BEMA]
obese_PRED
or_CC
overweight_NN
:_:
one_CD
in_PIN
three_CD
Americans_NN
born_VBN [WZPAST]
in_PIN
2000_CD
will_PRMD
become_VB
diabetic_JJ
._.
Forty_CD
two_CD
million_CD
people_NN
worldwide_JJ
live_VPRT
with_PIN
HIV_NN
._.
Our_FPP1
181771_CD
compound_NN
is_VPRT [BEMA]
an_DT
appetite_NN
suppressant_NN
that_TSUB
creates_VPRT
a_DT
natural_JJ
feeling_GER
of_PIN
fullness_NOMZ
while_OSUB
our_FPP1
SGLT2_CD
inhibitor_NN
is_VPRT [BEMA]
a_DT
new_JJ
approach_NN
to_PIN
diabetes_NN
treatment_NOMZ
._.
GSK_NN
also_RB
has_VPRT
development_NOMZ
compounds_NN
against_PIN
HIV_NN
in_PIN
all_QUAN
phases_NN
of_PIN
its_PIT
replication_NOMZ
cycle_NN
._.
Our_FPP1
CEDD_NN
structure_NN
Vaccines_NN
Metabolic_NN
&_CC
Viral_NN
diseases_NN
Respiratory_NN
&_CC
Inflammatory_NN
diseases_NN
Microbial_NN
,_,
Musculoskeletal_NN
&_CC
Cardiovascular_NN
&_CC
Urogenital_NN
diseases_NN
Neurological_NN
&_CC
Gastrointestinal_NN
diseases_NN
Psychiatry_NN
Biopharmaceuticals_NN
Proliferative_NN
diseases_NN
Cancer_NN
affects_VPRT
one_CD
in_PIN
three_CD
people_NN
._.
Our_FPP1
572016_CD
compound_NN
,_,
Our_FPP1
new_JJ
CEDD_NN
was_VBD [PASS]
launched_VBN
in_PIN
January_NN
2004_CD
with_PIN
the_DT
aim_NN
of_PIN
extending_VBG
a_DT
dual_JJ
kinase_NN
inhibitor_NN
being_VBG [WZPRES] [PASS]
investigated_VBN
for_PIN
the_DT
treatment_NOMZ
GSKs_NN
R&D_NN
model_NN
through_PIN
monoclonal_JJ
antibodies_NN
,_,
therapeutic_JJ
vaccines_NN
and_CC
of_PIN
solid_JJ
tumors_NN
,_,
is_VPRT [BEMA]
a_DT
first_JJ
of_PIN
its_PIT
kind_NN
._.
It_PIT
may_POMD
help_VB
convert_VB
the_DT
recombinant_JJ
therapeutic_JJ
proteins_NN
._.
Biopharmaceuticals_NN
is_VPRT [BEMA]
a_DT
field_NN
where_RB
we_FPP1
are_VPRT
Cardiovascular_NN
disease_NN
is_VPRT [BEMA]
the_DT
number_NN
one_CD
killer_NN
in_PIN
the_DT
western_JJ
management_NOMZ
of_PIN
some_QUAN
cancers_NN
to_PIN
chronic_JJ
stable_JJ
disease_NN
states_NN
._.
progressing_VBG [PRESP]
a_DT
growing_VBG
number_NN
of_PIN
assets_NN
in_PIN
our_FPP1
early_TIME
stage_NN
pipeline_NN
._.
world_NN
and_CC
a_DT
growing_VBG
problem_NN
in_PIN
developing_VBG
countries_NN
as_RB
well_RB
._.
We_FPP1
are_VPRT [BEMA]
pioneering_PRED
a_DT
novel_JJ
class_NN
of_PIN
compounds_NN
that_DEMO
sharply_RB
lower_JJ
the_DT
activity_NOMZ
of_PIN
an_DT
enzyme_NN
associated_VBN [WZPAST]
with_PIN
cardiovascular_JJ
Diseases_NN
in_PIN
our_FPP1
CEDD_NN
portfolio_NN
encompass_VB
some_QUAN
of_PIN
the_DT
worlds_NN
Psychiatric_JJ
illnesses_NOMZ
include_VPRT
schizophrenia_NN
,_,
anxiety_NN
and_PHC
addiction_NOMZ
._.
This_DEMO
new_JJ
approach_NN
could_POMD
lead_VB
to_PIN
the_DT
next_JJ
generation_NOMZ
highest_JJ
un-met_JJ
medical_JJ
needs_NN
multiple_JJ
sclerosis_NN
,_,
Alzheimers_NN
The_NN
mission_NN
of_PIN
our_FPP1
CEDD_NN
is_VPRT
to_TO
provide_VB
direction_NOMZ
and_PHC
light_NN
to_PIN
the_DT
minds_NN
of_PIN
drugs_NN
to_TO
reduce_VB
cardiovascular_JJ
events_NN
and_PHC
deaths_NN
._.
disease_NN
,_,
irritable_JJ
bowel_NN
syndrome_NN
and_PHC
migraine_NN
._.
Our_FPP1
compound_NN
of_PIN
patients_NN
lost_VBN [WZPAST]
in_PIN
the_DT
shadow_NN
of_PIN
psychiatric_JJ
illnesses_NOMZ
._.
353162_CD
is_VPRT [BEMA]
our_FPP1
next_JJ
406381_CD
targets_NN
inflammatory_JJ
and_PHC
neuropathic_JJ
pain_NN
and_CC
is_VPRT [PASS]
expected_VBN [PRIV]
generation_NOMZ
noradrenaline_NN
dopamine_JJ
re-uptake_NN
inhibitor_NN
NDRI_NN
,_,
a_DT
new_JJ
to_TO
lead_VB
to_PIN
greater_JJ
effectiveness_NOMZ
across_PLACE
a_DT
range_NN
of_PIN
pain_NN
types_NN
._.
anti-depressant_JJ
with_PIN
the_DT
potential_NN
for_PIN
greater_JJ
control_NN
of_PIN
symptoms_NN
._.
The_DT
Research_NN
&_CC
Development_NOMZ
meetings_GER
The_DT
path_NN
to_PIN
products_NN
GSKs_NN
R&D_NN
is_VPRT [PASS]
structured_VBN
to_TO
take_VB
CEDDs_NN
that_TSUB
emphasise_VPRT
flexibility_NOMZ
and_CC
unveiled_VBD
to_PIN
analysts_NN
._.
Thirty_CD
five_CD
GSKs_NN
goal_NN
is_VPRT
to_TO
bring_VB
more_EMPH
than_PIN
advantage_NN
of_PIN
size_NN
at_PIN
the_DT
beginning_GER
therapeutic_JJ
focus_NN
._.
promising_JJ
compounds_NN
,_,
selected_VBN
20_CD
NCEs_NN
to_TO
phase_VB
III_NN
development_NOMZ
and_PHC
end_NN
of_PIN
the_DT
R&D_NN
process_NN
where_RB
for_PIN
novelty_NN
,_,
impact_NN
on_PIN
disease_NN
and_CC
over_IN
the_DT
next_JJ
three_CD
years_NN
,_,
leading_VBG
large-scale_JJ
research_NN
is_VPRT [PASS]
needed_VBN
The_DT
CEDD_NN
structure_NN
aims_VPRT
to_TO
make_VB
commercial_JJ
potential_NN
,_,
were_VBD [PASS]
outlined_VBN
._.
to_PIN
an_DT
anticipated_JJ
record_NN
number_NN
such_JJ
as_IN
screening_VBG
targets_NN
against_PIN
the_DT
R&D_NN
process_NN
more_EMPH
effective_JJ
and_CC
Some_QUAN
of_PIN
these_DEMO
compounds_NN
are_VPRT [BEMA]
of_PIN
filings_GER
in_PIN
the_DT
next_JJ
five_CD
years_NN
._.
It_PIT
is_VPRT
compounds_NN
and_CC
conducting_VBG
largeefficient_JJ
,_,
and_ANDC
our_FPP1
broad_JJ
and_PHC
deep_JJ
featured_VBN
on_PIN
this_DEMO
page_NN
along_IN
with_PIN
expected_VBN [PRIV]
that_THVC
over_IN
20_CD
of_PIN
these_DEMP
have_VPRT
scale_NN
clinical_JJ
trials_NN
._.
However_CONJ
,_,
to_TO
bridge_VB
pipeline_NN
is_VPRT [BEMA]
an_DT
early_TIME
sign_NN
of_PIN
the_DT
images_NN
from_PIN
our_FPP1
R&D_NN
organization_NOMZ
._.
the_DT
potential_JJ
to_TO
reach_VB
blockbuster_NN
the_DT
interface_NN
between_PIN
discovery_NN
and_PHC
evolution_NOMZ
in_PIN
this_DEMO
approach_NN
._.
status_NN
of_PIN
annual_JJ
sales_NN
of_PIN
$_$
1_CD
billion_CD
development_NOMZ
,_,
the_DT
organization_NOMZ
is_VPRT
GSK_NN
currently_RB
has_VPRT
148_CD
projects_NN
in_PIN
600_CD
million_CD
._.
divided_VBN [PASTP]
into_PIN
small_JJ
biotech-like_JJ
In_PIN
December_NN
,_,
R&D_NN
presentations_NOMZ
were_VBD [BEMA]
clinical_JJ
development_NOMZ
,_,
comprising_VBG [PRESP]
83_CD
business_NOMZ
units_NN
called_VBN
Centres_NN
of_PIN
made_VBN
in_PIN
the_DT
UK_NN
and_PHC
USA_NN
,_,
where_RB
new_JJ
chemical_NN
entities_NOMZ
,_,
45_CD
product_NN
line_NN
Excellence_NN
for_PIN
Drug_NN
Discovery_NN
GSK_NN
's_POS
pipeline_NN
of_PIN
future_JJ
products_NN
was_VBD
extensions_NN
and_CC
20_CD
vaccines_NN
._.
